Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep766 | Pituitary and Neuroendocrinology | ECE2022

A paradox in clinical practice: the case of a hidden tubercoloma

Parolin Matteo , Parisotto Matteo , uliana ambra , Sartorato Paola , Menis Ernesto De

Introduction: A potential cause of panhypopituitarism could be cerebral tubercular lesions, that are often misdiagnosed. Hormonal effects could be related directly to primary tubercular lesions, or after starting antitubercular therapy. Paradoxical reaction (PR) in tuberculosis is defined as clinical or radiological worsening of pre-existing tuberculous lesions or development of new lesions after beginning an appropriate antitubercular therapy (ATT). It has been suggested that...

ea0099p575 | Thyroid | ECE2024

Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) with aspirate parathormone (PTH): a case report and review of the literature

Parolin Matteo , Caruso Antonino , Sartorato Paola , Fusaroli Pietro , Pasquale De Menis Ernesto

Introduction: The prevalence of primary hyperparathyroidism is increasing owing to the more the routinely measurements of serum calcium. A single benign para-thyroid adenoma is the most frequent cause of sporadic PHPT. Primary hyperparathyroidism can also be due to ectopic mediastinal parathyroid adenoma in 11-25% of patients, more frequently involving inferior parathyroid translated in anterior mediastinum. In general to detect ectopic adenoma recent guidelines recommend the ...

ea0070aep1066 | Hot topics (including COVID-19) | ECE2020

Effect of long term rhgh treatment on bone mineral density in patients with childhood onset growth hormone deficiency

Dassie Francesca , Spinazze Alice , Russo Lucia , Parolin Matteo , Mioni Roberto , Maffei Pietro , Zaccaria Marco , Vettor Roberto , De Carlo Eugenio

Background: RhGH treatment in adults with childhood onset growth hormone deficiency (COGHD) affect bone metabolism over time according to gender and age. A long-term study of bone mass density (BMD) in young-middle age hypopituitary patients with COGHD may better highlight possible benefits of therapy and improve clinical follow up.Methods: We enrolled 40 adults (age range during follow-up: 16.8–36 years, F: 38%) with COGHD with at least 20 years o...

ea0063gp50 | Acromegaly and GH | ECE2019

Sleep disorders and cognitive dysfunction in acromegaly

Dassie Francesca , Wennberg Alexandra , Lorusso Riccardina , Parolin Matteo , Russo Lucia , Mazzocut Sara , Benavides-Varela Silvia , De Carlo Eugenio , Martini Chiara , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: In the general population, sleep disorders are associated with an increased risk of cognitive impairment; moreover, people with dementia often have sleep disturbances. The prevalence of sleep disorders, such as sleep apnea, in acromegalic patients is higher than in the general population, and they may have a higher risk of cognitive impairment due to acromegaly treatment (i.e. Radiotherapy) or cardiovascular comorbidities. In the literature, data about the relation...

ea0063p256 | Pituitary and Neuroendocrinology 1 | ECE2019

Hyperglycemia and pasireotide lar in acromegaly: a study with continuous glucose monitoring

Russo Lucia , Mazzocut Sara , Dassie Francesca , Parolin Matteo , Martini Chiara , Carlo Eugenio De , Fallo Francesco , Mioni Roberto , Vettor Roberto , Maran Alberto , Maffei Pietro

Background: Pasireotide LAR is a multireceptor targeted somatostatin analogue that has been shown to obtain a better biochemical control of acromegaly. However, pasireotide LAR could induce hyperglycemia in acromegalic patients with higher baseline glucose values. The devices that can track interstitial glucose levels such as continuous glucose monitoring (CGM) could be a useful for studying the impact of SSA on patientsÂ’ glucose status.Aim: We aime...

ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019

Pegvisomant: daily versus non daily administration a single centre real life study

Dassie Francesca , Rosson Marco , Parolin Matteo , Russo Lucia , Mazzocut Sara , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Fallo Francesco , Vettor Roberto , Maffei Pietro

Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...

ea0041ep903 | Pituitary - Clinical | ECE2016

Acromegalic cardiomyopathy: echocardiographic and CMR analysis

Casara Alvise , Dassie Francesca , Battocchio Marialberta , Parolin Matteo , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Famoso Giulia , Tona Francesco , Fallo Francesco , Vettor Roberto , Corbetti Francesco , Maffei Pietro

Introduction: Acromegalic cardiomyopathy is characterized by myocardial hypertrophy and interstitial myocardial fibrosis at biopsy. We studied left ventricular hypertrophy -LVH- through echocardiography (-ECHO- 2-D standard echocardiography and Doppler analysis) and cardiac magnetic resonance (CMR) analysis. Myocardial fibrosis was studied with late enhancement technique (LE) and extracellular volume technique (ECV) at CMR.Methods: 25 patients -pts- (13 ...